phospho p38 mapk thr180 tyr182 d3f9 xp rabbit mab  (Cell Signaling Technology Inc)

Journal: Biomedicines

Article Title: The Effects of the Levosimendan Metabolites OR-1855 and OR-1896 on Endothelial Pro-Inflammatory Responses

doi: 10.3390/biomedicines11030918

Figure Lengend Snippet: Impact of levosimendan, OR-1855, and OR-1896 on endothelial inflammatory MAPK signalling. Endothelial cells were pre-incubated with levosimendan, OR-1855, OR-1896 (10 µM; 30 min.), or sham solution (DMSO v/v ) followed by stimulation with IL-1β (10 ng/mL) for 30 min before lysis and subsequent western blotting. ( a ) Levosimendan, OR-1855, and OR-1896 decreased IL-1β-dependent phosphorylation of p38 MAPK (n = 4). ( b ) Levosimendan, OR-1855, and OR-1896 decreased IL-1β-dependent phosphorylation of ERK1/2 MAPK (n = 4–5). ( c ) OR-1855 and OR-1896 diminished IL-1β-dependent phosphorylation of JNK (n = 15), while levosimendan had no effect (n = 15). ( d ) Levosimendan, OR-1855, and OR-1896 decreased IL-1β-dependent phosphorylation of cjun (AP-1) (n = 7). The graphs show protein band densities of phosphorylated forms of the MAP Kinases and cjun normalized to GAPDH (* p < 0.05).

Article Snippet: Rabbit phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP™ (#4511), rabbit VCAM-1 (#12367), rabbit phospho-ERK1/2 (#4307), rabbit phospho-JNK (#4668), rabbit phospho-cjun (#320T), rabbit β-Actin (13E5) (#4790) antibodies were from Cell Signaling Technology (Leiden, the Netherlands).

Techniques: Incubation, Lysis, Western Blot